InvestorsHub Logo
Followers 828
Posts 119591
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Friday, 11/09/2018 6:46:10 PM

Friday, November 09, 2018 6:46:10 PM

Post# of 293
SITC data—Melanoma PIVOT-02 ORR=53%* (20*/38)—24% (9/38) CRs:

PR:
https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-presents-new-clinical-and-preclinical-data

CC slides:
https://t.co/cnESfELNnp

Of the 33 patients with known (pre-treatment) PD-L1 status, ORR was: 43% (6/14) in PD-L1-negative patients; and 68% (13/19) in PD-L1-positive patients.

*One additional responder relative to the SITC abstract, which was 50% (19/38).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTR News